

Stephen D Weigand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4570015/publications.pdf>

Version: 2024-02-01

67
papers

5,688
citations

168829

31
h-index

116156

66
g-index

67
all docs

67
docs citations

67
times ranked

7682
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 441-452.	1.4	8
2	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. <i>Alzheimer's and Dementia</i> , 2022, 18, 635-644.	0.4	28
3	Leftâ€Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. <i>Journal of Magnetic Resonance Imaging</i> , 2022, , .	1.9	3
4	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. <i>NeuroImage: Clinical</i> , 2022, 34, 102999.	1.4	11
5	Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. <i>Neurology</i> , 2022, 98, .	1.5	10
6	Response to â€œOn the reproducibility of quantitative susceptibility mapping and its potential as a clinical biomarker: A comment on Cogswell etâ€Al. 2021â€ NeuroImage, 2022, 251, 118992.	2.1	0
7	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2022, 37, 702-712.	2.2	14
8	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	1.5	5
9	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. <i>Acta Neuropathologica</i> , 2022, 144, 159-160.	3.9	14
10	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	2.1	63
11	Iron Heterogeneity in Early Active Multiple Sclerosis Lesions. <i>Annals of Neurology</i> , 2021, 89, 498-510.	2.8	22
12	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	1.8	12
13	<sc>NIAâ€AA</sc> Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	2.8	31
14	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	2.1	3
15	<sc>Magnetic Resonance Imaging</sc> Correlates of Multiple Sclerosis Immunopathological Patterns. <i>Annals of Neurology</i> , 2021, 90, 440-454.	2.8	12
16	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	2.2	4
17	Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. <i>Neurology</i> , 2021, 97, e1906-e1913.	1.5	18
18	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24

#	ARTICLE	IF	CITATIONS
19	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	1.5	11
20	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. <i>Neurobiology of Aging</i> , 2021, 110, 27-36.	1.5	7
21	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	3.7	74
22	Longitudinal Amyloid- β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	1.2	7
23	Sensitivity and Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	2.8	32
24	CSF biomarkers in Olmsted County. <i>Neurology</i> , 2020, 95, e256-e267.	1.5	14
25	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	1.4	46
26	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
27	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
28	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	1.5	51
29	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	3.8	223
30	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.5	62
31	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.4	14
32	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	3.9	65
33	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	2.8	32
34	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.5	55
35	[¹⁸ F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
36	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	3.7	218

#	ARTICLE	IF	CITATIONS
37	Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018, 39, 1052-1058.	1.2	14
38	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
39	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	3.7	309
40	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. <i>Acta Neuropathologica</i> , 2017, 133, 597-612.	3.9	53
41	Age-specific and sex-specific prevalence of cerebral β -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241
42	Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions. <i>Acta Neuropathologica</i> , 2017, 134, 45-64.	3.9	94
43	Brain tau deposition linked to systemic causes of death in normal elderly. <i>Neurobiology of Aging</i> , 2017, 50, 163-166.	1.5	2
44	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. <i>Neurology</i> , 2017, 89, 2271-2279.	1.5	30
45	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	4.9	159
46	[¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 124-133.	2.2	136
47	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. <i>NeuroImage</i> , 2017, 144, 113-127.	2.1	59
48	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.4	581
49	In vivo detection of connectivity between cortical and white matter lesions in early MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 973-981.	1.4	4
50	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1069-1082.	1.2	30
51	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	1.4	249
52	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.5	22
53	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	1.5	20
54	Updated TDP-43 in Alzheimer's disease staging scheme. <i>Acta Neuropathologica</i> , 2016, 131, 571-585.	3.9	244

#	ARTICLE	IF	CITATIONS
55	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology, The</i> , 2016, 15, 56-64.	4.9	104
56	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	1.4	10
57	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , 2016, 73, 85.	4.5	160
58	Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. <i>Annals of Neurology</i> , 2015, 78, 710-721.	2.8	485
59	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	1.2	19
60	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	1.8	10
61	Age, Sex, and APOE ϵ 4 Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	4.5	305
62	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	3.7	170
63	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	4.5	23
64	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.5	73
65	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.4	26
66	Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology, The</i> , 2014, 13, 997-1005.	4.9	297
67	18 F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	1.5	108